{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:04:47Z","timestamp":1795025087906,"version":"4.10.2"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118731","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:24:22Z","timestamp":1761963862000},"page":"118731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-5030","authenticated-orcid":false,"given":"Sally A.","family":"Fahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin M.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albeir","family":"Messiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashrakat Y.","family":"Nabawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Refaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa H.","family":"El-Maadawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118731_bib1","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.2147\/DMSO.S275898","article-title":"Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications","volume":"13","author":"Wondmkun","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2025.118731_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.dsx.2016.06.017","article-title":"Obesity and diabetes: an update","volume":"11","author":"Verma","year":"2017","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.biopha.2025.118731_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.biopha.2025.118731_bib4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s13679-023-00527-y","article-title":"Update on the obesity epidemic: after the sudden rise, is the upward trajectory beginning to flatten?","volume":"12","author":"Koliaki","year":"2023","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.biopha.2025.118731_bib5","unstructured":"Number of overweight or obese adults forecasts worldwide 2035 | Statista, (n.d.). \u3008https:\/\/www.statista.com\/statistics\/1386134\/number-of-overweight-or-obese-people-worldwide-forecasts\/\u3009 (accessed February 5, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nyas.14211","article-title":"Incretins in obesity and diabetes","volume":"1461","author":"Chia","year":"2020","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118731_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118731_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib11","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins","year":"2024","journal-title":"StatPearls"},{"key":"10.1016\/j.biopha.2025.118731_bib12","unstructured":"FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 | FDA, 2025. \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014\u3009 (accessed February 3, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (semaglutide): a new weight loss drug for chronic weight management","volume":"70","author":"Singh","year":"2022","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-8587(22)00349-7","article-title":"Glucagon, from past to present: a century of intensive research and controversies","volume":"11","author":"Scheen","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib15","series-title":"Semaglutide","author":"Kommu","year":"2024"},{"key":"10.1016\/j.biopha.2025.118731_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20163905","article-title":"Glucagon control on food intake and energy balance","volume":"20","author":"Al-Massadi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118731_bib17","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib18","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2017.10.09","article-title":"Semaglutide-the \u201c new kid on the block\u201d in the field of glucagon-like peptide-1 receptor agonists?","volume":"5","author":"Guja","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib19","unstructured":"FDA Approves New Medication for Chronic Weight Management | FDA, (n.d.). \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management\u3009 (accessed February 3, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib20","unstructured":"FDA Approves New Medication for Chronic Weight Management | FDA, (n.d.). \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management\u3009 (accessed March 1, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/00185787221125724","article-title":"Tirzepatide","volume":"58","author":"Baker","year":"2024","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.biopha.2025.118731_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S2213-8587(13)70183-9","article-title":"Bone loss after bariatric surgery: causes, consequences and management","volume":"2","author":"Stein","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1210\/jc.2017-01949","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia","volume":"103","author":"Christensen","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118731_bib26","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118731_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.biopha.2025.118731_bib34","doi-asserted-by":"crossref","first-page":"S-596","DOI":"10.1016\/S0016-5085(24)01838-9","article-title":"Sa1961 increased risk of de-novo gastroparesis in non-diabetic obese patients on glp-1 receptor agonists for weight loss: a multi-network study","volume":"166","author":"Mesgun","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118731_bib35","article-title":"Tendency of semaglutide to induce gastroparesis: a case report","volume":"16","author":"Chaudhry","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2025.118731_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc Med."},{"key":"10.1016\/j.biopha.2025.118731_bib37","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.apsb.2023.02.020","article-title":"A potentially serious adverse effect of GLP-1 receptor agonists","volume":"13","author":"Lu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2025.118731_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.biopha.2025.118731_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13717","article-title":"Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety","volume":"25","author":"M\u00fcllertz","year":"2024","journal-title":"Obes. Rev."},{"key":"10.1016\/j.biopha.2025.118731_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.biopha.2025.118731_bib41","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.biopha.2025.118731_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118731_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13717","article-title":"Potent incretin-based therapy for obesity: a systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety","volume":"25","author":"M\u00fcllertz","year":"2024","journal-title":"Obes. Rev."},{"key":"10.1016\/j.biopha.2025.118731_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.biopha.2025.118731_bib45","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.biopha.2025.118731_bib46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7570\/jomes22012","article-title":"The upcoming weekly tides (Semaglutide vs. Tirzepatide) against obesity: STEP or SURPASS?","volume":"31","author":"Jung","year":"2022","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.biopha.2025.118731_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118731_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib49","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118731_bib50","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.14572","article-title":"A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes","volume":"24","author":"Furihata","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib52","article-title":"Tirzepatide for weight reduction in chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118731_bib53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bph.15647","article-title":"Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting?","volume":"179","author":"Borner","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118731_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.biopha.2025.118731_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.14229","article-title":"A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data","volume":"15","author":"Du","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.biopha.2025.118731_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-024-00789-9","article-title":"Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database","volume":"25","author":"Yang","year":"2024","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2025.118731_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib58","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118731_bib60","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib61","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.endinu.2024.01.001","article-title":"Acute pancreatitis due to different semaglutide regimens: an updated meta-analysis","volume":"71","author":"Masson","year":"2024","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"10.1016\/j.biopha.2025.118731_bib63","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-023-01086-x","article-title":"Association between glycemic status and the risk of acute pancreatitis: a nationwide population-based study","volume":"15","author":"Cho","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.biopha.2025.118731_bib64","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-12-0111","article-title":"GLP1 and cancer: friend or foe?","volume":"19","author":"Vangoitsenhoven","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.biopha.2025.118731_bib65","first-page":"45","article-title":"Drug-induced acute pancreatitis: a review","volume":"15","author":"Jones","year":"2015","journal-title":"Ochsner J."},{"key":"10.1016\/j.biopha.2025.118731_bib66","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/dom.12879","article-title":"Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes","volume":"19","author":"Kirk","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib67","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1753-0407.13252","article-title":"Targeting the PI3K\/Akt signaling pathway in pancreatic \u03b2-cells to enhance their survival and function: an emerging therapeutic strategy for type 1 diabetes","volume":"14","author":"Camaya","year":"2022","journal-title":"J. Diabetes"},{"key":"10.1016\/j.biopha.2025.118731_bib68","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib70","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1502047","article-title":"A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118731_bib72","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jdiacomp.2015.12.027","article-title":"Incidence and prevalence of thyroid dysfunction in type 1 diabetes","volume":"30","author":"Nederstigt","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.biopha.2025.118731_bib73","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1464-5491.1995.tb00553.x","article-title":"Frequency of thyroid dysfunction in diabetic patients: value of annual screening","volume":"12","author":"Perros","year":"1995","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib74","doi-asserted-by":"crossref","unstructured":"C. Cristina Silva Sousa Vergara Palma, M. Pavesi, V. Guedes Nogueira, E. Le\u00e3o Silva Clemente, M. de F\u00e1tima Bevilacqua Motta Pereira Vasconcellos, L. Carlos Pereira J\u00fanior, F. Faissol Pacheco, T. Gomide Braga, L. de Faria Bello, J. Oliveira Soares, S. Cathren Fenizola dos Santos, V. Paes Leme Cavalcante Campos, M. Brito Gomes, Prevalence of thyroid dysfunction in patients with diabetes mellitus, 2013. \u3008http:\/\/www.dmsjournal.com\/content\/5\/1\/58\u3009.","DOI":"10.1186\/1758-5996-5-58"},{"key":"10.1016\/j.biopha.2025.118731_bib75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00592-006-0204-8","article-title":"Thyroid dysfunction and thyroid autoimmunity in Saudi type 2 diabetics","volume":"43","author":"Akbar","year":"2006","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.biopha.2025.118731_bib76","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.15537\/1658-3175.2506","article-title":"Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan","volume":"25","author":"Radaideh","year":"2004","journal-title":"Saudi Med. J."},{"key":"10.1016\/j.biopha.2025.118731_bib77","doi-asserted-by":"crossref","DOI":"10.4021\/jocmr2010.03.281w","article-title":"Prevalence of thyroid dysfunction among greek type 2 diabetic patients attending an outpatient clinic","author":"Papazafiropoulou","year":"2010","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.biopha.2025.118731_bib78","article-title":"Subclinical hypothyroidism and type 2 diabetes: a systematic review and meta-analysis","volume":"10","author":"Han","year":"2015","journal-title":"PLOS One"},{"key":"10.1016\/j.biopha.2025.118731_bib79","doi-asserted-by":"crossref","first-page":"e4251","DOI":"10.1210\/clinem\/dgab183","article-title":"Causal association between serum thyrotropin and obesity: a bidirectional, mendelian randomization study","volume":"106","author":"Wang","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib80","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1507\/endocrj.EJ18-0140","article-title":"Association between serum thyrotropin within the euthyroid range and obesity","volume":"66","author":"Zhang","year":"2019","journal-title":"Endocr. J."},{"key":"10.1016\/j.biopha.2025.118731_bib81","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1786559","article-title":"Effect of liraglutide on serum TSH levels in patients with NAFLD and its underlying mechanisms","volume":"2022","author":"Ye","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.biopha.2025.118731_bib82","first-page":"275","article-title":"Exenatide treatment reduces thyroid gland volume, but has no effect on the size of thyroid nodules","volume":"16","author":"K\u00f6seo\u011flu","year":"2020","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib83","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000501895","article-title":"The effect of exenatide on thyroid-stimulating hormone and thyroid volume","volume":"8","author":"Sencar","year":"2019","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.biopha.2025.118731_bib84","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2025.118731_bib85","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/thy.2023.0284","article-title":"GLP-1 Receptor signaling has different effects on the perikarya and axons of the hypophysiotropic thyrotropin-releasing hormone synthesizing neurons in male mice","volume":"34","author":"Ruska","year":"2024","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.biopha.2025.118731_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2024.102185","article-title":"Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report","author":"Wilcox","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.biopha.2025.118731_bib87","first-page":"8","article-title":"Semaglutide-induced subclinical hypothyroidism: a case report","volume":"5","author":"Mazokopakis","year":"2023","journal-title":"Eur. J. Med. Health Sci."},{"key":"10.1016\/j.biopha.2025.118731_bib88","doi-asserted-by":"crossref","unstructured":"G.Kaylee Yu, S. Nakhle, N.John Vernetti, A. Chao, Thyroid FRI483 changes in thyroid function test with tirzepatide use in patients with hypothyroidism, J Endocrine Soc 7 (n.d.). https:\/\/doi.org\/10.1210\/jendso\/bvad114.","DOI":"10.1210\/jendso\/bvad114.1829"},{"key":"10.1016\/j.biopha.2025.118731_bib89","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118731_bib90","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0257","article-title":"Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?","volume":"12","author":"Lisco","year":"2023","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.biopha.2025.118731_bib91","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0192623312472402","article-title":"On-target Effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice","volume":"41","author":"Rosol","year":"2013","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2025.118731_bib92","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide \u2014 the FDA\u2019s review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib93","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/dmrr.1202","article-title":"The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review","volume":"27","author":"Aroda","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.biopha.2025.118731_bib94","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (ozempic) therapy for diabetes mellitus and obesity: a systematic literature review","volume":"25","author":"Feier","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118731_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/biom14060687","article-title":"Implications of GLP-1 receptor agonist on thyroid function: a literature review of its effects on thyroid volume, risk of cancer, functionality and TSH levels","volume":"14","author":"Capuccio","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118731_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111580","article-title":"Tirzepatide\u2014friend or foe in diabetic cancer patients?","volume":"12","author":"Samuel","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118731_bib97","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.118731_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170197","article-title":"GIP and the gut-bone axis \u2013 physiological, pathophysiological and potential therapeutic implications","volume":"125","author":"Stensen","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2025.118731_bib99","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1210\/jc.2015-1176","article-title":"GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women","volume":"100","author":"Iepsen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.biopha.2025.118731_bib101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/medicines9090047","article-title":"The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a pilot study","volume":"9","author":"Singh","year":"2022","journal-title":"Medicines"},{"key":"10.1016\/j.biopha.2025.118731_bib102","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/medicina58020224","article-title":"The impact of GLP1 agonists on bone metabolism: a systematic review","volume":"58","author":"Daniilopoulou","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.biopha.2025.118731_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopha.2025.118731_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170197","article-title":"GIP and the gut-bone axis \u2013 physiological, pathophysiological and potential therapeutic implications","volume":"125","author":"Stensen","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2025.118731_bib105","doi-asserted-by":"crossref","first-page":"E729","DOI":"10.1210\/jc.2013-3766","article-title":"A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk","volume":"99","author":"Torekov","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115553","article-title":"The role of endogenous GIP and GLP-1 in postprandial bone homeostasis","volume":"140","author":"Helsted","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2025.118731_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.921353","article-title":"Bone response to weight loss following bariatric surgery","volume":"13","author":"Mele","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/11795514241238059","article-title":"Gut-derived peptide hormone analogues and potential treatment of bone disorders in obesity and diabetes mellitus","volume":"17","author":"Ali","year":"2024","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.biopha.2025.118731_bib109","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1\u20137 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib110","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib111","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc22-1889","article-title":"Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.118731_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.673976","article-title":"The risk threshold for hemoglobin A1c associated with albuminuria: a population-based study in China","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118731_bib113","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfz106.FP482","article-title":"FP482EGFR loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from sustain 6 and leader","volume":"34","author":"Perkovic","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biopha.2025.118731_bib114","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2023","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.biopha.2025.118731_bib115","article-title":"264-OR: effect of tirzepatide on kidney function in people with excess body weight and type 2 diabetes\u2014a post-hoc analysis of the SURMOUNT-2 trial","volume":"73","author":"HEERSPINK","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118731_bib116","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib117","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/dc23-0261","article-title":"Effects of tirzepatide versus insulin glargine on cystatin C\u2013based kidney function: a SURPASS-4 post hoc analysis","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.118731_bib118","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1210\/endo.136.12.7588327","article-title":"Reduction of penile nitric oxide synthase in diabetic BB\/WORdp (type I) and BBZ\/WORdp (type II) rats with erectile dysfunction","volume":"136","author":"Vernet","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2025.118731_bib119","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1476-5381.2010.00825.x","article-title":"Insulin resistance in penile arteries from a rat model of metabolic syndrome","volume":"161","author":"Contreras","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118731_bib120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.fertnstert.2007.01.116","article-title":"Erectile dysfunction: does insulin resistance play a part?","volume":"88","author":"Trussell","year":"2007","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.biopha.2025.118731_bib121","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4111\/kju.2006.47.9.917","article-title":"Insulin resistance and erectile dysfunction","volume":"47","author":"Kim","year":"2006","journal-title":"Korean J. Urol."},{"key":"10.1016\/j.biopha.2025.118731_bib122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bju.15313","article-title":"Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses","volume":"128","author":"Mostafaei","year":"2021","journal-title":"BJU Int."},{"key":"10.1016\/j.biopha.2025.118731_bib123","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118731_bib124","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13300-022-01360-7","article-title":"Semaglutide in obesity: unmet needs in men","volume":"14","author":"Jensterle","year":"2023","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2025.118731_bib125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/dom.16042","article-title":"Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism","volume":"27","author":"Gregori\u010d","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib126","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/medicina60010050","article-title":"Impact of GLP-1 agonists on male reproductive health\u2014a narrative review","volume":"60","author":"Varnum","year":"2023","journal-title":"Medicina"},{"key":"10.1016\/j.biopha.2025.118731_bib127","article-title":"The effects of semaglutide vs testosterone replacement therapy on functional hypogonadism and sperm quality in men with type 2 diabetes mellitus and obesity","volume":"99","author":"Gregoric","year":"2024","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.biopha.2025.118731_bib128","article-title":"Effects of GLucagon-like Peptide-1 Analogs on Sexual Desire: A Randomized, double-blind, placebo-controlled crossover trial","volume":"90","author":"Lengsfeld","year":"2023","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.biopha.2025.118731_bib129","article-title":"Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study","author":"Able","year":"2024","journal-title":"Int. J. Impot Res."},{"key":"10.1016\/j.biopha.2025.118731_bib130","article-title":"Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: a single-center study","volume":"2","author":"Srinivasan","year":"2022","journal-title":"Obes. Pillars"},{"key":"10.1016\/j.biopha.2025.118731_bib131","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.3390\/jcm12185921","article-title":"Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs","volume":"12","author":"Carmina","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib132","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.3390\/jcm12144575","article-title":"The potential utility of tirzepatide for the management of polycystic ovary syndrome","volume":"12","author":"Anala","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib133","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2352-4642(23)00033-0","article-title":"Semaglutide and social media: implications for young women with polycystic ovarian syndrome","volume":"7","author":"Keating","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.biopha.2025.118731_bib134","unstructured":"EMA statement on ongoing review of GLP-1 receptor agonists | European Medicines Agency (EMA), 2025. \u3008https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists\u3009 (accessed February 7, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib135","unstructured":"Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity | FDA, 2025. \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type\u3009 (accessed February 7, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib136","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024 | European Medicines Agency (EMA), 2025. \u3008https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024\u3009 (accessed February 7, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib137","unstructured":"Wegovy, other weight-loss drugs scrutinized over reports of suicidal thoughts | Reuters, 2025. \u3008https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/wegovy-other-weight-loss-drugs-scrutinized-over-reports-suicidal-thoughts-2023-09-28\/\u3009 (accessed February 8, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib138","unstructured":"EMA Requests More Data from GLP-1 Drugmakers in Suicidal Ideation, Self-Harm Probe - BioSpace, 2025. \u3008https:\/\/www.biospace.com\/ema-requests-more-data-from-glp-1-drugmakers-in-suicidal-ideation-self-harm-probe\u3009 (accessed February 7, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib139","unstructured":"Wegovy | European Medicines Agency (EMA), 2025. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wegovy\u3009 (accessed February 7, 2025)."},{"key":"10.1016\/j.biopha.2025.118731_bib140","unstructured":"Fda, Medication Guide WEGOVY \u00ae (wee-GOH-vee) (semaglutide) injection, for subcutaneous use, 2022."},{"key":"10.1016\/j.biopha.2025.118731_bib141","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from world health organization data on semaglutide, liraglutide, and suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biopha.2025.118731_bib142","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib143","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis","volume":"79","author":"Liu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopha.2025.118731_bib144","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the food and drug administration adverse event reporting system (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.biopha.2025.118731_bib145","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/14740338.2024.2335215","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.biopha.2025.118731_bib146","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s43440-021-00274-8","article-title":"Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression","volume":"73","author":"Detka","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2025.118731_bib147","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/oby.22209","article-title":"Combined treatment for obesity and depression: a pilot study","volume":"26","author":"Faulconbridge","year":"2018","journal-title":"Obesity"},{"key":"10.1016\/j.biopha.2025.118731_bib148","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/jpgm.JPGM_712_16","article-title":"Psychiatric disorders and obesity: a review of association studies","volume":"63","author":"Rajan","year":"2017","journal-title":"J. Post. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/ph16070994","article-title":"Is there a risk for semaglutide misuse? Focus on the food and drug administration\u2019s FDA adverse events reporting system (FAERS) pharmacovigilance dataset","volume":"16","author":"Chiappini","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118731_bib150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopha.2025.118731_bib151","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/wps.20771","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopha.2025.118731_bib152","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2337\/dc24-0411","article-title":"Suicidal ideation, suicide attempts, and suicide deaths in adolescents and young adults with type 1 diabetes: a systematic review and meta-analysis","volume":"47","author":"Renaud-Charest","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.118731_bib153","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M23-2240","article-title":"Suicide attempts after a diagnosis of polycystic ovary syndrome: a cohort study","volume":"177","author":"Hsu","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib154","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pcd.2024.05.005","article-title":"Glucagon-like peptide receptor agonists and risk for depression","volume":"18","author":"Tagliapietra","year":"2024","journal-title":"Prim. Care Diabetes"},{"key":"10.1016\/j.biopha.2025.118731_bib155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/PPA.S124181","article-title":"Depressive symptoms and adherence to cardiometabolic therapies across phases of treatment among adults with diabetes: the diabetes study of northern California (DISTANCE)","volume":"11","author":"Bauer","year":"2017","journal-title":"Patient Prefer Adher."},{"key":"10.1016\/j.biopha.2025.118731_bib156","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/03007995.2020.1860358","article-title":"The rapid mood screener (RMS): a novel and pragmatic screener for bipolar I disorder","volume":"37","author":"McIntyre","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.biopha.2025.118731_bib157","article-title":"Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes","volume":"9","author":"Kanai","year":"2024","journal-title":"Obes. Pillars"},{"key":"10.1016\/j.biopha.2025.118731_bib158","article-title":"Wernicke encephalopathy associated with semaglutide use","volume":"16","author":"Sheth","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2025.118731_bib159","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.biopha.2025.118731_bib160","first-page":"139","article-title":"Saudi Arabia (4) Medical Student, Albaha University, Saudi Arabia (5) BPH, Ministry of Health, Saudi Arabia Citation: Abdullah Khlofh Saleh et al. Acute hemolytic anemia following semaglutide injection: a case report","volume":"20","author":"Khlofh Saleh","year":"2022","journal-title":"Fam. Med. Program"},{"key":"10.1016\/j.biopha.2025.118731_bib161","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0946","article-title":"Use of SGLT2 inhibitors vs GLP-1 RAs and ANemia in Patients with Diabetes and CKD","volume":"7","author":"Hu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biopha.2025.118731_bib162","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1463-1326.2012.01606.x","article-title":"Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis","volume":"14","author":"Liu","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib163","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-4162","article-title":"Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib164","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","volume":"2017","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2025.118731_bib165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118731_bib166","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.biopha.2025.118731_bib167","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.946133","article-title":"Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: is starvation the culprit?","volume":"25","author":"Bitar","year":"2024","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.biopha.2025.118731_bib168","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pcad.2024.12.010","article-title":"Anti-consumption agents: tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy","volume":"89","author":"O\u2019Keefe","year":"2025","journal-title":"Prog. Cardiovasc Dis."},{"key":"10.1016\/j.biopha.2025.118731_bib169","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib170","unstructured":"Diabetes Obesity and Metaboli - 2024 - Idris - Real world data showed that the dual GLP gip agonist Tirzepatide is, 2024."},{"key":"10.1016\/j.biopha.2025.118731_bib171","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41433-021-01741-5","article-title":"Semaglutide and the risk of diabetic retinopathy\u2014current perspective","volume":"36","author":"Sharma","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2025.118731_bib172","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118731_bib173","article-title":"Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: is starvation the culprit?","volume":"25","author":"Bitar","year":"2004","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.biopha.2025.118731_bib174","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pcad.2024.12.010","article-title":"Anti-consumption agents: tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy","volume":"89","author":"O\u2019Keefe","year":"2025","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.biopha.2025.118731_bib175","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118731_bib176","unstructured":"Diabetes Obesity and Metaboli - 2024 - Idris - Real world data showed that the dual GLP gip agonist Tirzepatide is, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118731_bib177","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2025.118731_bib178","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2025.118731_bib179","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1438318","article-title":"Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis","volume":"16","author":"Karimi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118731_bib180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/fps.79","article-title":"Novel GLP-1 mimetics in diabetes: lixisenatide and albiglutide","volume":"12","author":"Seewoodhary","year":"2011","journal-title":"Future Prescriber"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:58:46Z","timestamp":1777013926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":180,"alternative-id":["S0753332225009254"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118731","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118731"}}